Recombinant Proteins Market

Global Recombinant Proteins Market Size

The global recombinant proteins market size was valued at USD 2.78 billion in 2024 and is estimated to reach USD 5.37 billion by 2033 from USD 2.99 billion in 2025, registering a CAGR of 7.6% from 2025 to 2033.

MARKET PLAYERS

The rising prevalence of chronic diseases worldwide, especially cancer is majorly propelling the global recombinant proteins market growth.

According to the data provided by the World Health Organization, in 2022, there were an estimated 20 million new cancer cases and 9.7 million deaths. The number of people who were alive within five years following a cancer diagnosis was 53.5 million. Additionally, it also stated that about 1 in 5 people develop cancer in their lifetime, and approximately 1 in 9 men and 1 in 12 women die from the disease. The growing successful results of protein-based treatments for various chronic diseases are boosting the global market growth rate. The growing awareness in the healthcare industry regarding various applications of recombinant proteins is enhancing their demand in the healthcare sector. The recombinant proteins have broad applications in research, and they can be used as drugs in the treatment of various chronic diseases such as genetic disorders, autoimmune diseases, diabetes, cerebral apoplexy, and others, which is escalating the demand for recombinant protein therapeutics in the healthcare industry leading to market growth.

The rising collaborations and partnerships among the market players and the healthcare organizations and research institutes to develop innovations by enhancing the protein effects in the treatment and binding create opportunities for market expansion. The researchers are focusing on developing further generations of proteins where the third generation comprises enhanced properties such as specificity, new formulations, and new routes of administration with higher efficacy and safety. Product innovations and improvisations are the primary factors contributing to the recombinant proteins market growth. The prominent increase in research activities in biologics led to increased sales of recombinant proteins, accelerating the market growth opportunities.

MARKET RESTRAINTS

The complexity in the production of the recombinant protein, where there are high chances of proteolysis, incorrect folding, formation of inclusion bodies, or protein aggregation, is a major factor restraining the growth of the recombinant proteins market. Due to these conditions, the protein loses its natural structure. It needs to be addressed with specific strategies for each condition, which will be challenging for the researchers in the development process. The high costs associated with protein production due to slow cell production and expensive media and culture conditions hamper the global market growth. The need for more skilled personnel with extensive knowledge of gene cloning, protein expression, and equipment and resources is a challenge in expanding the market. The scaling up of the production from successful laboratory experiments to industrial scale enhances the complexity and resource requirements which will be challenging for the manufacturers and investors with budget restrictions. The presence of stringent regulations by the regulatory authorities for product approval acts as a significant challenge for manufacturers due to complex processes and high expenditure.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Host Cell Insights

The mammalian systems segment held the largest share in the global recombinant proteins market in 2024 and is expected to maintain its dominance during the forecast period. The increasing demand for proteomics and biologics is enhancing the value of mammalian protein expression, leading to segment growth. Mammalian cell expression systems are widely used for industrial applications due to their ability to produce larger quantities of high-quality protein, fueling the segment revenue growth. The rising prevalence of cancer and other chronic diseases is enhancing the production of biopharmaceutical products, which contributes to expanding the segment growth rate.

By Application Insights

The therapeutics segment dominated the recombinant proteins market with a prominent share and is estimated to grow steadily during the forecast period. The increasing demand for protein-based treatment owing to the prevalence of chronic diseases and genetic disorders is escalating the demand for protein-based therapeutics, leading to segment revenue growth. Protein-based therapeutics provide highly effective treatment for diabetes, cancer, and other diseases, boosting the demand for the therapeutics segment in the recombinant proteins market.

The drug discovery and development segment is expected to grow fastest during the forecast period. The increased utilization of recombinant proteins in wide research for the production of various therapeutic drugs in the treatment of various genetic and chronic diseases is increasing the growth opportunities for the segment.

By Products & Services​​​ Insights

The product segment held the most significant share of the global market in 2024 and is likely to hold the domination in the global market throughout the forecas period due to its usage in various healthcare and research sectors. The extensive usage of products in various fields, such as cancer, HIV/AIDS, and the recent pandemic COVID-19, immunology, and neuroscience, is augmenting the market growth in this segment. Cytokines and growth factors play a significant role in cancer research, enhancing the growth opportunities for the segment in the coming years.

The production services segment is projected to grow the fastest during the forecast period. The increasing demand for protein expression due to its wide applications in the research industry is propelling the segment's growth.

By End-User Insights

The pharma and biotechnology companies segment dominated the market with a significant share and is estimated to expand further with the highest CAGR during the forecast period. These companies' rising investments in developing various biosimilars and biologics enhanced the R&D activities for recombinant proteins, creating opportunities for market growth. The rising advancements in bioprocessing tools, the growing pipeline of products, and the escalating new technologies in research are propelling the global market through this segment.

The academic and research institutes segment is projected to grow rapidly in the coming years due to increasing collaborations and partnerships among the major market players. These players' growing investments in research projects to develop various effective therapeutics are leading to the substantial growth of recombinant proteins.

REGIONAL ANALYSIS

The North American region is also expected to continue its domination during the forecast period. The rising prevalence of cancer in the region, increasing R&D activities, well-established research institutes and the pharmaceutical industry, and significant market players are accelerating the market growth opportunities in the region. The growing government support initiatives are enhancing the regional market share. The presence of a robust healthcare infrastructure and huge rising investments in drug discovery and development are augmenting the growth rate of the North American market.

The European region held the second-largest market share in the global market due to its well-established healthcare infrastructure systems. The region is expected to have a prominent growth rate during the forecast period. Key market players in the region are fuelling the market growth owing to their initiatives in developing novel recombinant proteins.

The Asia Pacific region is expected to grow fastest during the forecast period due to increasing healthcare expenditure and growing investments in R&D activities across the region. The surge in chronic diseases and the increasing geriatric population are further fuelling the market growth in the region. Huge investments in research and increasing franchises of the major market players in the regional countries are increasing the market growth opportunities.

KEY MARKET PLAYERS

Abcam plc, R&D Systems Inc., GenScript, Bio-Rad Laboratories Inc., Merck KGaA, Thermo Fisher Scientific, Enzo Life Sciences Inc., STEMCELL Technologies Inc., RayBiotech Life Inc., and Sino Biological Inc. are some of the notable participants in the worldwide market.

RECENT MARKET HAPPENINGS

• In 2024, GenScript Biotech Corporation launched its latest AI innovations, including GenSmart Codon Optimization, a free online tool that enhances gene sequence design for improved expression across host organisms, mainly focusing on recombinant protein production.
• In 2024, Merck announced its investment in a new Life Science Research Center at its headquarters in Germany. The investment involves over USD 320.8 million for the research center.
• In July 2023, Dyadic International, Inc. announced an update regarding its Phase I Clinical Trial for the recombinant protein receptor binding domain (RBD) booster vaccine candidate DYAI-100 COVID-19. The Data Safety Monitoring Board (DSMB) stated the absence of certain significant vaccine-related safety concerns for both low—and high-dose groups.
• In May 2023, the National Medical Products Administration of China granted "Drug Clinical Trial Approval" to recombinant bivalent COVID-19 protein and trivalent COVID-19 trimeric protein vaccine.

MARKET SEGMENTATION

This research report on the global recombinant proteins market has been segmented and sub-segmented based on the following categories.

By Host Cell

• Mammalian Systems
• Insect Cells
• Yeast & Fungi
• Bacterial Cells
• Others

By Application

• Drug Discovery & Development
• Therapeutics
• Research
• Others

By Products & Services

• Products
• Production Services

By End-User

• Pharma & Biotechnology Companies
• Academic & Research Institutes
• Diagnostic Laboratories
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa